These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30728070)

  • 1. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
    Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
    Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
    García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
    Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
    Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA
    Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968
    [No Abstract]   [Full Text] [Related]  

  • 8. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
    Tsuji G; Okiyama N; Villarroel VA; Katz SI
    J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway.
    Zhang WB; Zhang HY; Jiao FZ; Wang LW; Zhang H; Gong ZJ
    Biomed Pharmacother; 2018 Jan; 97():818-824. PubMed ID: 29112935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
    Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
    Sakloth F; Manouras L; Avrampou K; Mitsi V; Serafini RA; Pryce KD; Cogliani V; Berton O; Jarpe M; Zachariou V
    Psychopharmacology (Berl); 2020 Jul; 237(7):2139-2149. PubMed ID: 32388618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
    Lee DH; Kim GW; Kwon SH
    Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy.
    Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S
    Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
    Amengual JE; Lue JK; Ma H; Lichtenstein R; Shah B; Cremers S; Jones S; Sawas A
    Oncologist; 2021 Mar; 26(3):184-e366. PubMed ID: 33458921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
    Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
    Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
    Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
    Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation.
    Chen C; Liu A; Lu Q; Luo L; Li J; Ke J; Liu Y; Feng X
    Chem Biol Interact; 2022 Feb; 353():109803. PubMed ID: 34998817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
    Lin CF; Hsu KC; HuangFu WC; Lin TE; Huang HL; Pan SL
    BMC Pharmacol Toxicol; 2020 Mar; 21(1):21. PubMed ID: 32178737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways.
    Zhang WB; Yang F; Wang Y; Jiao FZ; Zhang HY; Wang LW; Gong ZJ
    Biomed Pharmacother; 2019 Sep; 117():109166. PubMed ID: 31255993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
    Wu CP; Hsieh YJ; Murakami M; Vahedi S; Hsiao SH; Yeh N; Chou AW; Li YQ; Wu YS; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2018 Sep; 155():316-325. PubMed ID: 30028995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.